US Heart Valve Devices Market Report and Forecast 2026-2032

US Heart Valve Devices Market Insights & Analysis

The US Heart Valve Devices Market reached a value of nearly USD 11.32 billion in 2025. The market is assessed to grow at a CAGR of around 19.91%, during the forecast period of 2026-2032 to attain a value of around USD 33.65 billion in 2032. The industry is compelled by an uptick in the aging population, increasing prevalence of valvular heart diseases, and growing patient preference for minimally invasive procedures. Heart valve devices are medical implants utilized to treat conditions including one or more of the heart's four valves. Also, the major types include biological (tissue) valves & mechanical valves, while treatment measures typically involve either open surgery or transcatheter aortic valve replacement (TAVR).

Moreover, the US Heart Valve Devices Market has witnessed substantial innovation, remarkably in transcatheter heart valves, allowing for treatment with decreased recovery time & lesser procedural risk. Technological development, like the advancement of next-gen aortic valve systems & improved valve repair methods, continues to enhance patient outcomes. For example, new devices aiming on aortic valve replacement TAVR are progressively favored among elderly & high-risk patients.

Additionally, rising investment in the US Heart Valve Devices Market share by public & private sectors has extended research initiatives. Further, as market companies focus on expanding product portfolios via research & development, regulatory approvals support faster commercialization of state-of-the-art technologies. Also, increasing awareness of heart health & insurance coverage reforms would further support the industry. Hence, as a result, the US is projected to maintain its prominent position worldwide, ahead of regions like Asia Pacific and Latin America in the future years.

US Heart Valve Devices Market Upgrades & Recent Developments

2025:

• Boston Scientific Corporation declared an expansion of its aortic valve system portfolio with the launch of a next-generation transcatheter aortic valve replacement (TAVR) device, focused on enhancing durability & patient outcomes.
• Artivion, Inc. signed a strategic merger with a US-based cardiovascular device company to improve its tissue valve offerings & leverage advanced distribution channels.
• Shockwave Medical Inc., under Johnson & Johnson Services, Inc., declared new valve repair innovations integrating intravascular lithotripsy technology for patients with severe aortic stenosis.

US Heart Valve Devices Market Dynamics

• Driver: Growing Prevalence of Heart Diseases & Aging Population to Instigate Market Demand

The rising aging population in the US substantially contributes to the requirement for heart valve replacements, as elderly individuals are more prone to valvular disorders. Coupled with the rising prevalence of cardiovascular diseases, this trend drives the growth of the US Heart Valve Devices Industry.

• Challenge: Higher Price of Devices & Procedures to Hamper the Industry

Despite increasing demand, the higher expenses associated with aortic valve replacement, TAVR & transcatheter heart valve processes can limit patient access, specifically among the underinsured, creating a key industry obstacle.

• Opportunity: Technological Development & R&D Investments

Constant R&D has led to the making of more durable & proficient devices. These technological developments and improved investments are opening new avenues for innovative treatments & expanding the industry growth trajectory.

• Trend: Inclination towards Minimally Invasive Procedures to be Trending

Patients generally prefer minimally invasive procedures, such as TAVR, owing to lower hospital stays, fewer complications, and faster recovery, thus motivating acceptance rates & shaping future modernizations.

The US Heart Valve Devices Market Segment-Wise Analysis

By Valve Type:

• Biological (Tissue) Valve
• Mechanical Valve

The Biological (tissue) Valve segment is expected to uphold the largest share of the US Heart Valve Devices Market during the forecast period. Animal tissue is utilized to make tissue valves, which offer a more natural hemodynamic function.  For elderly individuals, they are perfect because they do not require long-term anticoagulant medication.  It is projected that the requirement for tissue valves would increase considerably as the population ages. Also, the progression of the market is driven by developments in aortic valve technology & novel transcatheter heart valve generations.  Further, a move toward minimally invasive procedures & a rising prominence on patients’ quality of life make biological valves the favored choice in the US.

By Procedure:

• Open Surgery
• Minimally Invasive Surgery (MIS)

The Minimally Invasive Surgery (MIS) segment is the dominant procedural category in the US Heart Valve Devices Market, due to the increasing adoption of TAVR. The recovery period, pain, and difficulty rates linked to open surgery are largely reduced by this method. The industry is fueled by patient knowledge & fondness for less intrusive procedures, as well as the FDA's increasing support for MIS techniques. Also, the MIS segment's supremacy is foreseen to grow throughout the forecast period, owing to the ongoing developments in transcatheter aortic valve replacement technology & the broadening of TAVR eligibility needs.

What Does Our US Heart Valve Devices Market Research Study Entail?

• The US Heart Valve Devices Market Research Report highlights the forecast growth rate (CAGR) by anticipating the market size and share.
• The market analysis puts light upon the primary industry trends, driving aspects, potential opportunities, growth challenges, and other major factors.
• The US Heart Valve Devices Market Research Report entails details about the most critical shifts in market share in the prominent regions.
• Considering the statistics & the developments by the primary market competitors, our report also strives to demonstrate the most sought-after strategies of the key players.